• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Matt Salo Explains the Impact Sovaldi Has on State Medicaid

Video

Despite being used to dealing with drugs that are incredibly expensive, the high cost of Sovaldi presents a new problem for state Medicaid programs, according to Matt Salo, the executive director of the National Association of Medicaid Directors.

Despite being used to dealing with drugs that are incredibly expensive, the high cost of Sovaldi presents a new problem for state Medicaid programs, according to Matt Salo, the executive director of the National Association of Medicaid Directors.

The problem, he explained, isn’t that the drug costs so much, because treatments for kids with cystic fibrosis are much more; the problem is that it costs so much and is needed for so many people.

“It’s not going to work within the limited finite budget that is Medicaid, because that means something else is going to have to give,” Mr Salo said. “If you double the pharmacy spend, what’s going to give? Long-term care? Nursing homes for seniors? Vaccinations for kids?”

Related Videos
Dr Julie Patterson, National Pharmaceutical Council
Diana Isaacs, PharmD
Beau Raymond, MD
Binod Dhakal, MD, Medical College of Wisconsin, lead CARTITUDE-4 investigator
Dr Sophia Humphreys
Robert Zimmerman, MD
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Ryan Stice, PharmD
Raajit Rampal, MD, PhD, screenshot
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.